Plain-English translation of NCT06597526 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether two types of imaging scans—called 18F-FDG and 68Ga-FAPI PET/CT scans—can help doctors better understand how well conversion therapy is working in patients with gastric cancer that has spread to the abdominal lining (called peritoneal metastasis). These scans may help doctors decide when you're ready for surgery and monitor whether the cancer comes back after treatment.
Right now, doctors need better tools to see exactly how well treatment is working and to catch cancer recurrence early in patients with this advanced form of gastric cancer. This study explores whether these imaging scans can provide clearer information than current methods.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have imaging scans at different points during your treatment journey. You'll receive one scan before starting conversion therapy and another as a baseline. Before your surgery, you'll have two more scans to help your doctors assess treatment response. If your cancer returns after surgery, you would have two additional scans. In total, most participants will have 4 scans; those with recurrence may have up to 6. Your doctors will also review your medical records and collect basic information like height and weight.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Sponsor
Ruijin Hospital
Enrollment target
~30 participants
Started
June 2024
Primary completion
March 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jiajia Hu
Ruijin Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.